HAIFA, Israel, Sept. 6, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that Company executives will be presenting at five leading scientific and financial events in the U.S. during the month of September. The presentations will focus on Pluristem's work towards the potential development of placenta-derived stem cell treatments for a variety of illnesses as well as on the company's strategy.
During the month of September, Pluristem will be presenting at the following conferences:
-
35th Annual Meeting of the AATB - September 8-12, Scottsdale, Arizona.
Dr. William R. Prather, Sr. VP Corporate Development, will present: "The use of Placenta-derived MSCs in the treatment of radiation exposure" on Sunday, September 11, 2011 from 3:15 to 4:15 PM
-
Rodman & Renshaw Conference - September 11-13, New York, New York.
Yaky Yanay, VP Finance and CFO, will present: "Cell Therapy and Its Future Role in Reducing Healthcare Spending" on Tuesday, September 13, 2:00-2:25 PM, Sutton Suite
-
UBS Global Life Sciences Conference - September 19-21, New York, New York.
Zami Aberman, Chairman and CEO, will present the Company on Tuesday, September 20, 2011 at 4:00 PM
-
The Cell Therapy Commercialization Summit - September 19-21, 2011, Boston, Massachusetts.
Dr. William R. Prather, Sr. VP of Corporate Development, will present the Company on Monday, September 19, 2011, 9:00-9:30 AM
-
8th Annual Israel Strategic Partner and Venture Conference-Life Sciences and Medical Devices - September 22, 2011, Princeton, New Jersey.
Dr. William R. Prather, Sr. VP of Corporate Development, will present the Company
-
European Society of Cardiology: International Conference on Heart Failure with Preserved Ejection Fraction: Basic mechanisms - September 23-25, Budapest, Hungary.
Frida Grynspan, PhD, VP of Research and Development, will present: "HFPEF and stem cells" Session VII – Therapy, on Sunday, September 25, 2011 10:20-10:40 AM.
About Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading bio-therapeutics company, developing standardized cell therapy products for the treatment of life threatening diseases. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching prior to administration. Data from two phase I studies indicate that Pluristem's first PLX product candidate, PLX-PAD, is safe and potentially effective for the treatment of end stage peripheral artery disease. Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage, when administered locally, and in inflammatory bowel disease, MS and stroke, when administered systemically.
Pluristem has a strong patent portfolio, GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team.
For more information visit www.pluristem.com, or follow us on Twitter @Pluristem, the contents of which are not part of this press release.
The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements when we speak about our potential development of placenta-derived stem cell treatments for a variety of illnesses or when we say that data from two Phase I clinical trials indicate that Pluristem's first PLX product, PLX-PAD, is safe and potentially effective for the treatment of end stage PAD or that Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.